Metrics as of 10/13/2026, 06:53 PM (Berlin time), refresh in progress.
OmniAb Stock
OmniAb, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Matthew W. Foehr
- Employees
- 89
- Market cap
- $694 M
- IPO
- 30/09/2021
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of…
OmniAb stock: price history
1D
+0.2%
1W
+9.9%
1M
+17.5%
6M
+227.5%
YTD
+158.5%
1Y
+195.2%
2Y
+18.4%
5Y
-51.9%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~27% stronger price swings than usual
Ask the agents about OmniAb
Analyst assessment of OmniAb
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
11
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 07/10/2026
OmniAb stock metrics
P/E
-13.29
P/B
2.37
EV/EBITDA
-34.37
RETURN ON EQUITY
-2.3%
NET MARGIN
-43.7%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.7%
FLOAT SHARES
118,435,310
AVG. DAILY VOLUME (30D)
1,439,544
Insider transactions (SEC)
HIGGINS JOHN L
Love Steven
Bertozzi Carolyn R
Cochran Jennifer R.
Gotwals Philip J
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.2%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about OmniAb stock
What does OmniAb do?
OmniAb, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Matthew W. Foehr, the company employs around 89 people.
The IPO was on 30/09/2021; the stock trades on NASDAQ under the ticker OABI.
What do analysts say about OmniAb stock?
11 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does OmniAb report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 27% stronger than usual.
Does OmniAb pay a dividend?
No, OmniAb currently does not pay a dividend.
Which stocks are comparable to OmniAb?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get OmniAb stock analyzed?
Clicking "Analyze stock" lets five strategies assess OmniAb against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.